References
- Wunsch H, Angus DC, Harrison DA, et al. Variation in critical care services across North America and Western Europe. Crit Care Med. 2008;36(10):2787–2793. .
- Helbing D, Brockmann D, Chadefaux T, et al. Saving human lives: what complexity science and information systems can contribute. J Stat Mech. 2015;158(3):735–781.
- Halpern NA, Bettes L, Greenstein R. Federal and nationwide intensive care units and healthcare costs: 1986–1992. Crit Care Med. 1994;22(12):2001–2007.
- Moerer O, Plock E, Mgbor U, et al. A German national prevalence study on the cost of intensive care: an evaluation from 51 intensive care units. Crit Care. 2007;11(3):R69.
- Oostenbrink JB, Buijs-Van der Woude T, van Agthoven M, et al. Unit costs of inpatient hospital days. PharmacoEconomics. 2003;21(4):263–271.
- Carson SS, Cox CE, Holmes GM, et al. The changing epidemiology of mechanical ventilation: a population-based study. J Intensive Care Med. 2006;21(3):173–182.
- Lefrant J-Y, Garrigues B, Pribil C, et al. The daily cost of ICU patients: a micro-costing study in 23 French intensive care units. Anaesth Crit Care Pain Med. 2015;34(3):151–157.
- McLaughlin AM, Hardt J, Canavan JB, et al. Determining the economic cost of ICU treatment: a prospective “micro-costing” study. Intensive Care Med. 2009;35(12):2135–2140.
- Altawalbeh SM, Saul MI, Seybert AL, et al. Intensive care unit drug costs in the context of total hospital drug expenditures with suggestions for targeted cost containment efforts. J Crit Care. 2017;44:77–81.
- Halpern NA, Pastores SM. Critical care medicine in the United States 2000–2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med. 2010;38(1):65–71.
- Kane-Gill SL, Kirisci L, Verrico MM, et al. Analysis of risk factors for adverse drug events in critically ill patients*. Crit Care Med. 2012;40(3):823–828.
- Kane-Gill SL, Jacobi J, Rothschild JM. Adverse drug events in intensive care units: risk factors, impact, and the role of team care. Crit Care Med. 2010;38(6 Suppl):S83–89.
- The hashemite kingdom of Jordan the high health council. The National Strategy for Health Sector in Jordan 2015–2019. Available from: http://www.hhc.gov.jo/uploadedimages/The%20National%20Strategy%20for%20Health%20Sector%20in%20Jordan%202015–2019.pdf
- World Health Organization. Jordan; 2016; Available from: https://www.who.int/countries/jor/en/
- Homoud L. Jordan pharmaceutical country profile. Ed.^(Eds). Ministry of Health of Jordan, World Health Organization; 2011.
- Nazer LH, Elaibaid M, Al-Qadheeb N, et al. Critical care research in the world health organization eastern mediterranean region over two decades: where do we stand? Intensive Care Med. 2018;44:1588–1590.
- Pastores SM, Dakwar J, Halpern NA. Costs of critical care medicine. Crit Care Clin. 2012;28(1):1–10.
- Weber RJ, Kane SL, Oriolo VA, et al. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med. 2003;31(1 Suppl):S17–24.
- Norris C, Jacobs P, Rapoport J, et al. ICU and non-ICU cost per day. Can J Anaesth. 1995;42(3):192–196.
- Flannery AH, Pandya K, Laine ME, et al. Managing the rising costs and high drug expenditures in critical care pharmacy practice. Pharmacotherapy. 2017;37(1):54–64.
- Williams A, Mathai AS, Phillips AS. Antibiotic prescription patterns at admission into a tertiary level intensive care unit in Northern India. J Pharm Bioallied Sci. 2011;3(4):531.
- Inan D, Saba R, Gunseren F, et al. Daily antibiotic cost of nosocomial infections in a Turkish university hospital. BMC Infect Dis. 2005;5(1):5.
- Abdulah R. Antibiotic abuse in developing countries. Pharm Regul Aff. 2012;1(2):1000e1106.
- Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. 2017;6:47.
- Alexander MR, Stumpf JL, Nostrant TT, et al. Albumin utilization in a university hospital. DICP. 1989;23(3):214–217.
- Aramwit P, Kasettratat N. Evaluation of serum albumin utilization in inpatient at a private hospital in Bangkok. Yakugaku zasshi. 2004;124(9):631–634.
- Magalhães FA, Chini LSN. Doubtful or unfunded indications observed with albumin treatment: a study in a teaching hospital in Rio de Janeiro State. Rev Bras Ter Intensiva. 2007;19(2):192–196.
- Matos G, Rozenfeld S, Martins M. Human albumin use at hospitals in the metropolitan region of Rio de Janeiro, Brazil. Cad Saude Publica. 2010;26(5):981–990.
- D BCPS AHTP. Evaluation of the pattern of human albumin utilization at a university affiliated hospital. Arch Iran Med. 2012;15(2):85.
- Charles A, Purtill M, Dickinson S, et al. Albumin use guidelines and outcome in a surgical intensive care unit. Arch Surg. 2008;143(10):935–939.
- Lyu PF, Hockenberry JM, Gaydos LM, et al. Impact of a sequential intervention on albumin utilization in critical care. Crit Care Med. 2016;44(7):1307–1313.
- Mahmoudi L, Karamikhah R, Mahdavinia A, et al. Implementation of pharmaceutical practice guidelines by a project model based: clinical and economic impact. Medicine (Baltimore). 2015;94(42):e1744.
- Martelli A, Strada P, Cagliani I, et al. Guidelines for the clinical use of albumin: comparison of use in two Italian hospitals and a third hospital without guidelines. Curr Ther Res. 2003;64(9):676–684.
- Mirici-Cappa F, Caraceni P, Domenicali M, et al. How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol. 2011;17(30):3479.
- Moghnieh R, Kanafani ZA, Kanj SS. Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine. J Thorac Dis. 2016;8(12):E1672–E1675.
- Alberti C, Brun-Buisson C, Goodman SV, et al. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med. 2003;168(1):77–84.
- Marshall JC, Vincent J-L, Guyatt G, et al. Outcome measures for clinical research in sepsis: a report of the 2nd cambridge colloquium of the international sepsis forum. Crit Care Med. 2005;33(8):1708–1716.
- Engel C, Brunkhorst FM, Bone H-G, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33(4):606–618.
- Kramer AA, Dasta JF, Kane-Gill SL. The impact of mortality on total costs within the ICU. Crit Care Med. 2017;45(9):1457–1463.
- Burchardi H, Schneider H. Economic aspects of severe sepsis. PharmacoEconomics. 2004;22(12):793–813.
- Goussous S. 425 traffic accidents recorded in first three months of 2016. The Jordan Times (Ed.(Eds)). 2016. Amman.